Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Talking up throughout most cancers therapy helped one affected person handle uncomfortable side effects, tackle insurance coverage points and keep productive all through...
Dr. Julia E. McGuinness and Dr. Joshua Okay. Sabari talk about the SERENA-6 trial and its outcomes for sufferers with ESR1-mutated HR+/HER2— breast most...
